NCT06067490View on ClinicalTrials.gov

A Phase I Study of RC1416 Injection

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

June 29, 2023

Primary Completion Date

May 14, 2024

Study Completion Date

May 14, 2024

Conditions
Healthy Volunteers
Interventions
DRUG

RC1416(SAD)

RC1416(SAD),there are six doses(25mg-600mg) in this part. Each subjects will receive the drug once by subcutaneous injection.

DRUG

Placebo(SAD)

Placebo(SAD), Each subjects will receive the placebo once by subcutaneous injection.

Trial Locations (1)

100029

China-japan Friendship Hospital, Beijing

All Listed Sponsors
lead

Nanjing RegeneCore Biotech Co., Ltd.

INDUSTRY

NCT06067490 - A Phase I Study of RC1416 Injection | Biotech Hunter | Biotech Hunter